A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study

Biomarkers. 2013 Nov;18(7):607-13. doi: 10.3109/1354750X.2013.838305. Epub 2013 Sep 16.

Abstract

Objective: The potential development of a noninvasive marker predicting nonalcoholic steatohepatitis (NASH).

Methods: Thirty patients with biopsy-proven nonalcoholic fatty liver disease were evaluated by numerous anthropometric, clinical and biochemical parameters.

Results: Serum glutamic oxaloacetic transaminase (SGOT; p = 0.027), log (erythrocyte sedimentation rate) (ESR; p = 0.034) and homocysteine (p = 0.041) were associated with NASH independently from gender, age and body mass index. When combined, the regression model provided R(2) = 0.563 (p = 0.001) and area under the ROC curve = 0.873 ± 0.066 (p < 0.001).

Conclusion: This noninvasive marker, named HSENSI (acronym of homocysteine, SGOT, ESR, Nonalcoholic Steatohepatitis Index), consists of three low cost, easily measurable parameters and may accurately predict NASH.

MeSH terms

  • Aspartate Aminotransferases / blood
  • Biomarkers / blood
  • Blood Sedimentation
  • Cross-Sectional Studies
  • Fatty Liver / blood*
  • Fatty Liver / diagnosis
  • Female
  • Greece
  • Homocysteine / blood
  • Humans
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease
  • Pilot Projects
  • ROC Curve

Substances

  • Biomarkers
  • Homocysteine
  • Aspartate Aminotransferases